Heart Failure With Preserved, Borderline, and 406 Reduced Ejection Fraction: 5-Year Outcomes, J Am Coll Cardiol, 2017. ,
The average lifespan of patients discharged from hospital 409 with heart failure, J Gen Intern Med, 2012. ,
Medical Therapy for Heart Failure With Reduced 411 Ejection Fraction: The CHAMP-HF Registry, J Am Coll Cardiol, 2018. ,
Physicians' guideline adherence is associated 414 with long-term heart failure mortality in outpatients with heart failure with reduced 415 ejection fraction: the QUALIFY international registry, Eur J Heart Fail, 2019. ,
Contemporary Drug Treatment of 418 ,
, Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry, JACC, vol.419
, Hear Fail, 2019.
Eplerenone in patients with systolic heart failure 421 ,
The effect of spironolactone on morbidity and 423 mortality in patients with severe heart failure ,
, N Engl J Med, 1999.
Dapagliflozin in patients with heart 426 failure and reduced ejection fraction, N Engl J Med, 2019. ,
Angiotensin-Neprilysin Inhibition versus 428 ,
, Enalapril in Heart Failure, N Engl J Med, vol.371, pp.993-1004, 2014.
, Contemporary Treatment Patterns, p.430
, Clinical Outcomes of Comorbid Diabetes Mellitus and Heart Failure with Reduced 431
, Ejection Fraction: the CHAMP-HF Registry, JACC Heart Fail, vol.2020
Longitudinal Titration of Medical Therapy 433 for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry, J Am Coll 434 Cardiol, 2019. ,
Temporal Trends in the Incidence of and Mortality 436 ,
, Associated With Heart Failure With Preserved and Reduced Ejection Fraction, JACC, vol.437
, Hear Fail, 2018.
Angiotensin-neprilysin inhibition versus 439 enalapril in heart failure, N Engl J Med, 2014. ,
Active-control trials: How would a new agent compare 441 with placebo? A method illustrated with clopidogrel, aspirin, and placebo, Am Heart J, vol.442, 2001. ,
The use of putative placebo in active control trials: Two 444 applications in a regulatory setting, Stat Med, 2003. ,
Statistical methods for comparison to placebo in active-control 446 trials, Ther Innov Regul Sci, 2001. ,
A putative placebo analysis of the effects of 448 LCZ696 on clinical outcomes in heart failure, Eur Heart J, 2015. ,
Estimating the long-term treatment benefits 451 of sacubitril-valsartan, N Engl J Med, 2015. ,
, Am Coll Cardiol, 2019.
, MRAs in Elderly HF Patients: Individual, vol.455
, Hear Fail, vol.456, p.2019
Efficacy and safety of LCZ696 (sacubitril-valsartan) 458 according to age: Insights from PARADIGM-HF, Eur Heart J, vol.36, pp.2576-84, 2015. ,
Efficacy and Safety of Dapagliflozin in Heart 460 ,
, Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
, Circulation, 2020.
Thirty Years of Evidence on the Efficacy of Drug 463 ,
, Treatments for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-464
, Circ Hear Fail, Analysis, 2017.
Reduced Risk of hyperkalemia during treatment 466 of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan 467 compared with enalapril: A secondary analysis of the PARADIGM-HF trial, JAMA 468 Cardiol, 2017. ,
, , p.470
, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization
, JACC Heart Fail, 2019.
Expanding the scope of the 'polypill' to heart 473 failure, J Card Fail, 2013. ,
Communication Strategies for Sharing Prognostic 475 Information with Patients: Beyond Survival Statistics ,
, Pfizer Data Access Requests
, , 2020.
, Novartis Position on Clinical Study Transparency -Clinical Study Registration, Results 481 Reporting and Data Sharing